|
gptkbp:instanceOf
|
gptkb:drug
monoamine oxidase inhibitor
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
1982
|
|
gptkbp:ATCCode
|
gptkb:N04BD02
|
|
gptkbp:brand
|
gptkb:Eldepryl
gptkb:Emsam
gptkb:Zelapar
|
|
gptkbp:CASNumber
|
gptkb:14611-51-9
|
|
gptkbp:category
|
antiparkinsonian agent
antidepressant
|
|
gptkbp:chemicalFormula
|
C13H17N
|
|
gptkbp:contraindication
|
concomitant use with SSRIs
concomitant use with meperidine
concomitant use with tricyclic antidepressants
|
|
gptkbp:developedBy
|
gptkb:Hungary
|
|
gptkbp:discoveredBy
|
gptkb:Zoltan_Ecseri
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
10 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Selegiline
|
|
gptkbp:IUPACName
|
gptkb:(R)-N-methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine
|
|
gptkbp:KEGGID
|
D02315
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
irreversible MAO-B inhibitor
|
|
gptkbp:MeSH_ID
|
gptkb:D013033
|
|
gptkbp:metabolism
|
gptkb:desmethylselegiline
amphetamine
liver
|
|
gptkbp:molecularWeight
|
191.28 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribedWith
|
gptkb:levodopa
carbidopa
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1163
gptkb:DB01037
26757
24932
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
hypertensive crisis (with tyramine)
|
|
gptkbp:routeOfAdministration
|
oral
transdermal
|
|
gptkbp:sideEffect
|
nausea
dizziness
insomnia
hallucinations
|
|
gptkbp:synonym
|
gptkb:deprenyl
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|